Comparison of efficacy between adjuvant chemotherapy and chemoradiation therapy for pancreatic cancer: AJCC stage-based approach

Table 2 Cox proportional hazard regression analysis predicting overall survival

	Number of patients, n = 335	Median OS, mo (95%CI)	Univariable		Multivariable
			HR (95%CI)	P value	HR (95%CI)	P value
Age ≥ 70				0.145		0.218
No	237	35.1 (28.5-44.4)	1.00		1.00
Yes	98	26.9 (22.2-39.2)	1.24 (0.91-1.70)		1.29 (0.84-1.99)
Sex				0.226		0.394
Female	143	33.3 (27.1-46.1)	1.00		1.00
Male	192	32.3 (25.7-39.8)	1.21 (0.90-1.62)		1.14 (0.83-1.55)
ECOG				0.469		0.731
0	275	34.2 (27.8-42.4)	1.00		1.00
1	60	27.4 (19.1-39.8)	1.16 (0.79-1.69)		1.11 (0.74-1.65)
Charlson’s index ≥ 6				0.222		0.876
No	257	34.0 (28.5-39.8)	1.00		1.00
Yes	78	26.0 (22.2-50.8)	1.21 (0.87-1.68)		1.07 (0.68-1.67)
Safety margin ≤ 0.1 cm				0.032		0.345
No	209	35.9 (30.7-47.0)	1.00		1.00
Yes	126	26.9 (22.3-34.8)	1.41 (1.04-1.91)		1.18 (0.86-1.62)
Histology				0.077		0.038
WD/MD	292	33.9 (27.8-39.6)	1.00		1.00
PD/UD	32	18.0 (16.2-NA)	1.50 (0.94-2.40)		1.71 (1.04-2.82)
Lymphovascular invasion				< 0.001		< 0.001
No	137	60.9 (44.4-89.6)	1.00		1.00
Yes	196	25.3 (21.5-28.5)	2.14 (1.61-2.85)		1.91 (1.36-2.69)
Perineural invasion				< 0.001		0.590
No	55	59.3 (42.4-114.6)	1.00		1.00
Yes	280	30.6 (26.0-35.7)	1.73 (1.16-2.59)		1.17 (0.75-1.82)
AJCC stage
I	136	59.3 (39.6-82.1)	1.00	< 0.001		0.003
II	140	27.6 (23.0-34.8)	1.83 (1.32-2.54)		1.36 (0.96-1.94)
III	59	22.0 (16.3-27.4)	2.84 (1.93-4.18)		1.97 (1.29-3.01)
CA19-9 ≥ 100 U/mL				< 0.001		0.002
No	159	47.0 (34.0-90.6)	1.00		1.00
Yes	175	26.9 (22.5-33.6)	1.74 (1.30-2.33)		1.67 (1.21-2.30)

AJCC: American Joint Committee on Cancer; CA 19-9: Carbohydrate antigen 19-9; ECOG: Eastern Cooperative Oncology Group; MD: Moderately differentiated; NA: Not available; PD: Poorly differentiated; UD: Undifferentiated; WD: Well differentiated.